Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib Discontinuation and Re-Treatment in TGCT
NCT04526704Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 4 trial of pexidartinib in tenosynovial giant cell tumor (TGCT), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2020; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04526704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526704.